<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">

<head>
<meta content="text/html; charset=utf-8" http-equiv="Content-Type" />
<title>Rule-10TB</title>
</head>

<body>

<p><p style="margin: 0.5em 0px; line-height: 22.4px; color: rgb(0, 0, 0); font-family: sans-serif; font-size: 15px; font-style: normal;
font-variant: normal; font-weight: normal; letter-spacing: normal; orphans: auto; text-align: justify; text-indent: 0px; text-transform: none;
white-space: normal; widows: 1; word-spacing: 0px; -webkit-text-stroke-width: 0px; background-color: rgb(255, 255, 255);"><strong>Rule-10TB, Income-tax Rules:</strong><br />
<br />
[Eligible assessee.<br />
<br />
<strong>10TB</strong>.(1) Subject to the provisions of sub-rules (2) and (3), 
the 'eligible assessee' means a person who has exercised a valid option for 
application of safe harbour rules in accordance with rule 10TE, and—<br />
<br />
(i) is engaged in providing software development services or information 
technology enabled services or knowledge process outsourcing services, with 
insignificant risk, to a non-resident associated enterprise (hereinafter 
referred as foreign principal);<br />
<br />
(ii) has made any intra-group loan;<br />
<br />
(iii) has provided a corporate guarantee;<br />
<br />
(iv) is engaged in providing contract research and development services wholly 
or partly relating to software development, with insignificant risk, to a 
foreign principal;<br />
<br />
(v) is engaged in providing contract research and development services wholly or 
partly relating to generic pharmaceutical drugs, with insignificant risk, to a 
foreign principal; or<br />
<br />
(vi) is engaged in the manufacture and export of core or non-core auto 
components and where ninety per cent or more of total turnover during the 
relevant previous year is in the nature of original equipment manufacturer 
sales.<br />
<br />
(2) For the purposes of identifying an eligible assessee, with insignificant 
risk, referred to in item (i) of sub-rule (1), the Assessing Officer or the 
Transfer Pricing Officer, as the case may be, shall have regard to the following 
factors, namely:—<br />
<br />
(a) the foreign principal performs most of the economically significant 
functions involved, including the critical functions such as conceptualisation 
and design of the product and providing the strategic direction and framework, 
either through its own employees or through its other associated enterprises, 
while the eligible assessee carries out the work assigned to it by the foreign 
principal;<br />
<br />
(b) the capital and funds and other economically significant assets including 
the intangibles required, are provided by the foreign principal or its other 
associated enterprises, and the eligible assessee is only provided a 
remuneration for the work carried out by it;<br />
<br />
(c) the eligible assessee works under the direct supervision of the foreign 
principal or its associated enterprise which not only has the capability to 
control or supervise but also actually controls or supervises the activities 
carried out through its strategic decisions to perform core functions as well as 
by monitoring activities on a regular basis;<br />
<br />
(d) the eligible assessee does not assume or has no economically significant 
realised risks, and if a contract shows that the foreign principal is obligated 
to control the risk but the conduct shows that the eligible assessee is doing 
so, the contractual terms shall not be the final determinant;<br />
<br />
(e) the eligible assessee has no ownership right, legal or economic, on any 
intangible generated or on the outcome of any intangible generated or arising 
during the course of rendering of services, which vests with the foreign 
principal as evident from the contract and the conduct of the parties.<br />
<br />
(3) For the purposes of identifying an eligible assessee, with insignificant 
risk, referred to in items (iv) and (v) of sub-rule (1), the Assessing Officer 
or the Transfer Pricing Officer, as the case may be, shall have regard to the 
following factors, namely:—<br />
<br />
(a) the foreign principal performs most of the economically significant 
functions involved in research or product development cycle, including the 
critical functions such as conceptualisation and design of the product and 
providing the strategic direction and framework, either through its own 
employees or through its other associated enterprises while the eligible 
assessee carries out the work assigned to it by the foreign principal;<br />
<br />
(b) the foreign principal or its other associated enterprises provides the funds 
or capital and other economically significant assets including intangibles 
required for research or product development and also provides a remuneration to 
the eligible assessee for the work carried out by it;<br />
<br />
(c) the eligible assessee works under the direct supervision of the foreign 
principal or its other associated enterprise which has not only the capability 
to control or supervise but also actually controls or supervises research or 
product development, through its strategic decisions to perform core functions 
as well as by monitoring activities on a regular basis;<br />
<br />
(d) the eligible assessee does not assume or has no economically significant 
realised risks, and if a contract shows that the foreign principal is obligated 
to control the risk but the conduct shows that the eligible assessee is doing 
so, the contractual terms shall not be the final determinant;<br />
<br />
(e) the eligible assessee has no ownership right, legal or economic, on the 
outcome of the research which vests with the foreign principal and is evident 
from the contract as well as the conduct of the parties]</p>

</body>

</html>
